BRCA1 and neoplasm: According to these results, the patients with somatic mutations in BRCA1/2, detected in this study, could benefit from PARPi targeted therapy, since most cases are HGSOC present 100% representativeness in the tumor and, therefore, low levels of contamination by normal cells.